Corify Care is in search of capital to further develop. The spin-off of the Hospital General Universitario Gregorio Marañón and the ITACA Institute of Universitat Politècnica de Valencia, which has developed a medical device to diagnose arrhythmias, has opened a financing round of €600,000 through the Capital Cell platform, according to Andreu Climent, founder and CEO of the company.
Corify Care work with the aim of improving the effectiveness of treatments against cardiac arrhythmias. The Acorys® medical device allows mapping the heart in a non-invasive way for an accurate diagnosis of cardiac arrhythmias and the identification of its optimal treatment. The technology is patented and the clinical feasibility studies have been successful.
Corify Care is completing the development of Acorys® with the support of the Center for Industrial Technological Development (CDTI) of the Ministry of Industry, which has supported them with € 1M, and the European Institute of Innovation and Technology, which in addition to financing them with € 750,000 has awarded them as the most innovative project of the year 2020.
The Corify Care round will be 600,000 EUR, led by Genesis Biomed, on behalf of a family office in Barcelona that co-invests with 300,000 EUR. The objective of this round of Corify Care is to achieve the CE marking and start commercialization before 2023.
Corify Care’s pre-money valuation for this round is EUR 6M, with an expected exit in 2026 for EUR 150M and an expected multiplier for investors from the current round of X16.
The Corify Care round will be available at Capital Cell from February 26, 2021, with a 10% discount until March 17, 2021 or until the end of the round for investments of € 15,000 or more.
On February 25, 2021, at 6:00 p.m., Corify Care will make a Deal Üp! If you are interested in investing or you know someone who may be interested, please do not hesitate to register or write to mailto:email@example.com.
Source: Corify Care